An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination with Eribulin versus Eribulin alone in Patients with HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Study of HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS)
Sponsor: Polyphor
Enrolling: Male and Female Patients
IRB Number: AAAS7020
U.S. Govt. ID: NCT03786094
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine if the experimental drug balixafortide combined with eribulin is well tolerated and more effective for treating breast cancer compared with eribulin given alone. Balixafortide (POL6326) interacts with proteins called CXCR4 receptors which may directly suppress tumor growth through disruption of signaling pathways. Eribulin is FDA approved for the treatment of metastatic breast cancer.
This study is closed
Investigator
Melissa Accordino, MD
Do You Qualify?
Are you 18 years old, or older? Yes No
Do you have confirmed diagnosis of breast cancer that is metastatic or unresectable (cannot be removed through surgery)? Yes No
Is your breast cancer type HER2 negative? Yes No
Have you received between 1-4 chemotherapy regimens? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE